GlobeNewswire

PCI Biotech - release of the RNA Therapeutics Virtual Conference presentation

Share

Oslo (Norway), 10 February 2021 – PCI Biotech (OSE: PCIB), a clinical-stage biopharma company developing innovative therapeutics that address significant unmet medical needs in cancer today released the fimaNAc focused presentation for the 12th Annual RNA Therapeutics Virtual Conference, a UK based online event taking place February 10-11, 2021. The 2021 conference is set to explore the latest developments in RNA delivery agents and RNA-based therapeutics with the latest case studies on advanced mRNA technologies, oligonucleotide delivery, therapeutic applications and future trends and innovations. PCI Biotech is also a sponsor of the event.

Today, Wednesday February 10 2021, at 13:10pm (CET) Dr. Anders Høgset, CSO, will present an overview of PCI Biotech’s proprietary platform technology, focusing on the delivery of RNA molecules, including the most recent data on the use of the fimaNAc delivery technology in the exciting field of RNA based therapies.

Per Walday, CEO of PCI Biotech, comments: Encouraging collaborative preclinical results have recently been achieved with the fimaNAc technology and we are very pleased to be able to share these data now. The rapid development progress of mRNA-based vaccines against Covid-19 has generated much attention to the potential of nucleic acid therapeutics generally, and mRNA particularly. The results with fimaNAc suggests that this technology provides an appealing intracellular delivery solution for certain applications within this class of therapeutics.

An online recording of the full presentation held by Dr Høgset will be made available on PCI Biotech’s website (www.pcibiotech.com) under “Scientific publications & presentations” after the event.

Contact information:    
Per Walday, CEO            
pw@pcibiotech.no
Mobile: +47 917 93 429

About PCI Biotech
PCI Biotech is a biopharmaceutical late stage clinical development company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform.  PCI is applied to three distinct anticancer paradigms: fimaChem (enhancement of chemotherapeutics for localised treatment of cancer), fimaVacc (T-cell induction technology for therapeutic vaccination), and fimaNAc (nucleic acid therapeutics delivery).

Photochemical internalisation induces triggered endosomal release that is used to unlock the true potential of a wide array of therapeutic modalities. The company’s lead programme fimaChem consists of a pivotal study in bile duct cancer, an orphan indication with a high unmet need and without approved products. fimaVacc applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines, which works in synergy with several other state-of-the-art vaccination technologies. fimaNAc utilises the endosomal release to provide intracellular delivery of nucleic acids, such as mRNA and RNAi therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field.

For further information, please visit: www.pcibiotech.com

Forward-looking statements  

This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. PCI Biotech disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Attachment


About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

SEK CREDIT OPERATION ANNOUNCEMENT1.3.2021 10:30:00 CETPress release

Bid date, 2021-03-01Auction date2021-03-01Settlement date2021-03-01Maturity Date2021-05-31Term13 weeksInterest rateThe Riksbank´s applicable repo rateBid times11.00-11.30 (CET/CEST) on the Bid dateConfirmation of bids to e-maileol@riksbank.seOffered volumeUnlimitedThe lowest accepted bid volume50 million SEKMaximum number of bids1Allocation Time11.45 (CET/CEST) on the Bid date Stockholm, 2021-03-01 Bid date, 2021-03-01Auction date2021-03-01Settlement date2021-03-01Maturity Date2021-08-30Term26 weeksInterest rateThe Riksbank´s applicable repo rateBid times11.00-11.30 (CET/CEST) on the Bid dateConfirmation of bids to e-maileol@riksbank.seOffered volumeUnlimitedThe lowest accepted bid volume50 million SEKMaximum number of bids1Allocation Time11.45 (CET/CEST) on the Bid date Stockholm, 2021-03-01 This is a translation of the Swedish version published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language v

IBFD launches Talking Points, a fresh perspective on the latest tax developments1.3.2021 10:00:00 CETPress release

AMSTERDAM, March 01, 2021 (GLOBE NEWSWIRE) -- We are excited to announce the launch of Talking Points today, a brand new service that will provide IBFD users with market-leading commentary and analysis on the latest and hottest developments in international taxation. Talking Points will showcase thought leadership from around the world on key developments, news items and other important international tax topics. IBFD users will benefit from valuable insights, reasoning, opinions and viewpoints putting tax developments in perspective from some of the most prominent leaders in international taxation. Maarten Goudsmit, Publishing Director, IBFD, says, “We are excited to launch this new format. Talking Points will provide the tax community with timely, insightful commentary and analysis of the impact of the latest hot topics on daily practice, from leading industry experts.” To celebrate this launch, we will make the first article on Crossing the Digital Services Tax Divide – But Is It Wor

The Bonduelle Group specifies its mission and enshrines it in its articles of association: We inspire the transition toward a plant-based diet to contribute to people's well-being and planet health1.3.2021 10:00:00 CETPress release

Pressrelease Villeneuve d’Ascq, March 1, 2021 The Bonduelle Group specifies its mission and enshrines it in its articles of association. “We inspire the transition toward a plant-based diet to contribute to people's well-being and planet health”. At the presentation of its first half-year financial results for the 2020-2021 fiscal year on February 26, the Bonduelle Group presented its mission. Submitted to the shareholders' vote at the last Shareholders' Meeting, it was very widely approved (99.91%) and is now enshrined in the company's articles of association. It is intended to guide the group's future strategic choices and reinforces Bonduelle's long-term vision. It reaffirms the company's determination to play an active role in the socio-economic and environmental challenges of today and tomorrow. Towards a more resilient model that creates positive impacts Committed to the B Corp certification process and a founding member of the B Movement Builders, Bonduelle reaffirms its commitm

Net asset value as per February 28, 20211.3.2021 10:00:00 CETPress release

On February 28, 2021, net asset value was SEK 299 per share. The closing price on February 26, 2021, was SEK 300.00 for the Class A shares and SEK 278.90 for the Class C shares. Stockholm, March 1, 2021 AB INDUSTRIVÄRDEN (publ) For further information, please contact: Sverker Sivall, Head of Corporate Communication and Sustainability, tel. +46-8-666 64 00 Submitted for publication on March 1, 2021 at 10:00 a.m. Attachment Substansvarde_210301_eng

Agillic wins international gaming platform provider Multilot as a new client: Personalisation is the name of the game1.3.2021 09:00:00 CETPress release

Press release, Copenhagen, 1 March 2021 Agillic, a leading Danish omnichannel marketing software company, will help Multilot, a multinational SaaS gaming platform provider, build long-lasting customer relationships through automated and personalised communication across the customer lifecycle. Multilot offers a fully compliant turn-key gaming platform as a service (SaaS). They operate games, bingo, lotteries, raffles and games of chance on behalf of humanitarian organisations, associations, media houses and corporate partners. Multilot can manage the entire value chain, including assistance in applying for national gaming licenses, game development, assurance of compliance to laws and regulations, customer support, accounting and reporting to the authorities. Further, the company caretakes the direct communication with end-users. And it is for this purpose Multilot has chosen Agillic. Says Petter Danbolt CEO, Multilot: “Gaming is entertainment and fun, hopes and dreams. When we provide

GOGL – Private placement: issue of New Shares1.3.2021 08:34:35 CETPress release

1 March 2021, Hamilton, Bermuda Reference is made to the stock exchange release by Golden Ocean Group Limited (NASDAQ and OSE: GOGL) (“Golden Ocean” or the "Company”) on 17 February 2021 regarding completion of the private placement of new shares in the Company (the "Private Placement"). The new shares have been legally and validly issued and fully paid, and the Company's issued share capital has been increased to USD 9,924.012.20, divided into 198,480,244 issued shares, each with a nominal value of USD 0.05. The new shares are registered under a separate ISIN pending approval of a listing prospectus by the Financial Supervisory Authority of Norway, and will not be listed or tradable on the Oslo Stock Exchange until the listing prospectus is approved. For further queries, please contact: Ulrik Andersen: Chief Executive Officer, Golden Ocean Management AS +47 22 01 73 53 Peder Simonsen: Chief Financial Officer, Golden Ocean Management AS +47 22 01 73 45